Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer

Nicholson, Robert Ian, Hutcheson, Iain Robert, Harper, Maureen Elaine, Knowlden, Janice Mary, Barrow, Denise, McClelland, Richard Andrew, Jones, Helen E., Wakeling, A. E. and Gee, Julia Margaret Wendy ORCID: https://orcid.org/0000-0001-6483-2015 2001. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocrine-Related Cancer 8 (3) , pp. 175-182. 10.1677/erc.0.0080175

Full text not available from this repository.

Abstract

There is an increasing body of evidence demonstrating that growth factor networks are highly interactive with oestrogen receptor (ER) signalling in the control of breast cancer growth. As such, tumour responses to anti- hormones are likely to be a composite of the ER and growth factor inhibitory activity of these agents. The current article examines the modulation of growth factor networks during endocrine response, and presents in vitro and clinical evidence that epidermal growth factor receptor signalling, maintained in either an ER-dependent or -independent manner, is critical to anti- hormonal-resistant breast cancer cell growth. The considerable potential of the epidermal growth factor receptor-selective tyrosine kinase inhibitor, ZD 1839 (Iressa; AstraZeneca) to efficiently treat, and perhaps even prevent, endocrine-resistant breast cancer is highlighted.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy Biosciences
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Publisher:	Society for Endocrinology
ISSN:	1351-0088
Last Modified:	18 Oct 2022 14:20
URI:	https://orca.cardiff.ac.uk/id/eprint/17177

Citation Data

Cited 131 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item